

Intended Result	Your Report	Your Score
Specimen 8361 HIV-2 Ab positive	HIV-2 Ab positive	2
Specimen 8362 HIV-1 Ab positive	HIV-1 Ab and/or Ag positive	2
Specimen 8363 HIV-1 Ab positive	HIV-1 Ab and/or Ag positive	2
Specimen 8364 HIV-1/2 negative	HIV-1/2 Ag and Ab negative	2
Specimen 8365 HIV-1 p24 Ag positive and Ab positive	HIV-1 p24 antigen positive	2
Specimen 8366 HIV-1/2 negative	HIV-1/2 Ag and Ab negative	2

Cumulative score information

Total number of specimens sent to you for **UK NEQAS for HIV serology** over the last 3 distributions is 18
For these distributions specimen numbers 7969 7970 7971 7972 7973 7974 8214 8215 8216 8217 8218 8219 8361 8362 8363 8364 8365 8366 have been analysed and scored.



Number of reports analysed 18
Number of specimens reported as not examined (not scored) 0
Number of specimens received too late for analysis (not scored) 0
Number of specimens for which no report was received (not scored) 0
Your cumulative score for these specimens was 36 out of a possible total of 36

The mean score calculated from the reports returned by **UK** laboratories was 35.40 with a standard error of 1.75.

Performance rating

Your performance rating for **UK NEQAS for HIV serology** (i.e. the number of standard errors by which your cumulative score lies above or below the mean for UK laboratories) is 0.35.
A performance rating of more than 1.96 standard errors below the mean indicates possible poor performance. Your performance rating may change if other participants' results are amended.

No score penalty is incurred for non return of reports. However non return of results may be used as a measure of poor performance.



Comments: A total of 331 sets of specimens were distributed for testing with 311 (94.0%) participants returning results within the specified period. The overall performance was excellent with 98.1% of participants who returned their results reporting the intended results.

Prior to dispatch all samples in this distribution were tested using 5 different EIAs. In addition, the presence of antibodies to specific HIV proteins was determined using the BioRad New LAV Blot I and the Fujirebio INNO-LIA HIV 1/2 assays. The presence of HIV-1 p24 antigen is confirmed using the VIDAS HIV p24 assay. Pre-distribution test results are available should you experience a technical failure and wish to discuss the results.

Please refer to the comments pages 8-9 for further information .

In the histograms on page 2 and subsequent pages a maximum of 12 kits results are displayed: these include the most commonly used methods and the method(s) used in your laboratory indicated by an arrow(s). The figures in the histograms and those in the overall results tables may differ (1) due to exclusion of kits displayed in the histograms resulting in apparently lower numbers of data sets in the histograms or (2) due to participants using more than one kit resulting in higher numbers of data sets in the histograms.

Turn around time: The time taken to report your results was 0-days. This information is provided for your own use and does not form part of your performance assessment.

Enquiries: Any queries about this distribution can be addressed to Dr Sanjiv Rughooputh at organiser@ukneqasmicro.org.uk. For repeat specimens for EQA failure investigations please request using the web form at <https://ukneqasmicro.org.uk/participant-info/order-repeat-specimens/>.


Acknowledgements: We thank colleagues at the UKHSA Virus Reference Division at Colindale, UKHSA Manchester, NHS Blood and Transplant and the Microbiology Department at Gloucestershire Hospitals for assistance with the pre-distribution testing.

Report authorised by: Dr Sanjiv Rughooputh, Scheme Organiser.




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8361 HIV-2 Ab positive




Specimen : 8361 HIV-2 Ab positive




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8362 HIV-1 Ab positive




Specimen : 8362 HIV-1 Ab positive




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8363 HIV-1 Ab positive




Specimen : 8363 HIV-1 Ab positive




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8364 HIV-1/2 negative




Specimen : 8364 HIV-1/2 negative




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8365 HIV-1 p24 Ag and HIV-1 Ab positive




Specimen : 8365 HIV-1 p24 Ag and HIV-1 Ab positive




Six specimens were dispatched with the request to determine HIV-1/2 status. The specimens were derived from thrombinised human plasma (serum) donations. Specimens 8361, 8362, 8363 and 8365 consisted of HIV-1/ HIV-2 Ab positive donations / HIV-1 p24 antigen positive donation, diluted 30x, 14x, 11.25x and 1.8x, respectively, in HIV-1/2 negative donations. Specimens 8364 and 8366 consisted of HIV-1/2 negative human thrombinised plasma (serum). Bronidox at a final concentration of 0.05% was added as a preservative.

Specimen : 8366 HIV-1/2 negative



Specimen : 8366 HIV-1/2 negative



Comments on distribution 5551

Overall performance in this distribution was outstanding, with 98.1% of participants achieving the maximum score of 2. This is a decline of 1.2% on previous distribution 5504, where 99.3% of participants reported the intended results.

The return rate was very good. Of the 331 sets of specimens that were dispatched, 94% (311) participants returned their results within the deadline. This is a decline of 1.1% on previous distribution 5504, where the return rate was 95.1%.

Specimen 8361: HIV-2 Ab positive

Three hundred and ten (310) participants returned results for this specimen with 91.3% (283) obtaining the correct result. Amongst the 283 participants who obtained the correct result; 80.9% (229) reported this specimen as HIV-1/2 positive and 19.1% (54) as HIV-2 positive.

5.5% (17) of the participants who submitted a result, reported this specimen as HIV-1/2 indeterminate and obtained a score of 1. **Seven participants (2.3%) reported this specimen as HIV-1 positive and scored -1. Whilst, three participants (0.9%) reported this specimen as HIV-1/2 negative and scored -1.**

Specimens 8362, 8363 and 8365: HIV-1 Ab positive

Three hundred and nine (309) participants reported on specimens 8362 and 8365 respectively. Three hundred and ten participants reported on specimen 8363, with 99.7%, 100% and 99.4% reporting a correct result for these specimens respectively.

Specimen 8362: 218 (70.6%) participants reported HIV1/2 positive, 90 (29.1%) participants reported HIV 1 positive and obtained a maximum score of 2. **One (0.3%) participant reported as HIV-1/2 negative and obtained a score of -1.**

Specimen 8363: 219 (70.7%) participants reported HIV1/2 positive, 89 (28.7%) participants reported HIV 1 positive and obtained a maximum score of 2. **One (0.3%) participant reported as HIV-1/2 negative and obtained a score of -1. Another participant (0.3%) reported as HIV-1/2 p24 Ag positive and obtained a score of -1.**

Specimen 8365: 216 (69.9%) participants reported HIV1/2 positive, 91 (29.4%) participants reported HIV 1 positive, two participants reported HIV-1 p24 Ag positive and obtained a maximum score of 2.



Specimens 8364 and 8366: HIV-1/2 Negative

For specimen 8364 of the 310 participants who returned results, 99.7% (309) reported a negative result and obtained the maximum score of 2. **One participant reported a HIV1/2 positive result and obtained a score of -1.**

Three hundred and nine (309) participants reported on specimen 8366. Of these, 98.4% (304) reported a negative result and obtained the maximum score of 2. **Five participants (1.6%) reported as HIV-1/2 positive results and obtained score of -1.**

Investigating incorrect results and non-return of results

Participants who did not obtain the intended results are requested to investigate and report the plausible root cause by completing an incident review form (IRF) online within 30 days of this report being published. IRFs are taken into considerations when poor performance analysis is carried out for the National Quality Assurance Advisory Panel (NQAAP).

Non-return of results is considered as poor performance.

Participants who did not return their results should also complete an IRF. IRFs are available on the following link: <https://uknegasmicro.org.uk/incident-review-form/>

End of report

